Furthermore, we studied two groups within each mouse model, pre-blocking hPD-1 with non-radioactive pembrolizumab (blk) and not pre-blocking (nblk), in order to demonstrate the specificity and increased immunoPET tracer tumor (or xenograft) targeting in the nblk group. The gene discussed is PDCD1; the disease is neoplasm.